PeptideStack
5.2kquestions
20kanswers
220users

How many freeze-thaw cycles will dulaglutide at 3.33 mg/mL tolerate?

Asked 13 Jan 2026Modified 2 months agoViewed 10k times
5

What I am working with: dulaglutide · 3.33 mg/mL.

This is a procedural question rather than a theoretical one, and I would like the procedure rather than the theory.

What I have done so far is read the label documentation where it exists and the two pharmacopoeial monographs that are publicly available, which cover the licensed presentation and say nothing about a research one.

What would you do, and what would you check afterwards?

freeze-thaw
freeze-thaw

What repeated freezing does to a peptide in solution: ice-crystal shear at the growing front, freeze-concentration of solutes, pH shifts as buffer…

55 questions
peptide-stability
peptide-stability

The chemistry of peptide degradation: deamidation, oxidation, hydrolysis, aggregation and fibrillation, and how temperature, pH, ionic strength,…

832 questions
storage
storage

Storage conditions and their evidence base: minus twenty degrees for powder, refrigerated for solution, protection from light, and what the…

646 questions
shareeditfollowflag
AP
askedarea_percent13k1813 Jan 2026
7This should probably be in the site help pages rather than buried in an answer. – assay_blank 3 months ago
6Good answer, but the confidence interval in the cited trial is wider than implied. – ahmed_zerouali 34 days ago
add a comment

5 Answers

Accepted answer first, then by votes
20

Accepted answer

The relevant detail is that start by separating chemical degradation from physical degradation, because they fail differently and they are detected differently. Chemical degradation changes the molecule and shows up as new peaks on a chromatogram. Physical degradation aggregates the molecule and often shows up as nothing at all on reverse-phase HPLC, because the aggregate never makes it onto the column.

For the solid state, residual moisture is the dominant variable. A cake at two per cent water is considerably more stable than the same cake at six per cent, because water is both a reactant in hydrolysis and a plasticiser that lowers the glass transition temperature. This is why a desiccant in the outer packaging is not theatre, and why opening a cold vial in a humid room is a genuine error — you condense water onto the cake.

On re-freezing something that thawed in transit: if it arrived as a lyophilised solid that warmed but never got wet, re-freezing costs you nothing except the thermal cycle. If it arrived as a solution that thawed, re-freezing adds a second transition and therefore a second dose of ice-front shear. The asymmetry is worth internalising.

The licensed semaglutide and tirzepatide presentations carry in-use periods of several weeks at room temperature in their labelling, which is the closest thing to real stability data in this space — and it applies to a buffered, surfactant-containing, preservative-containing formulation, not to a reconstituted research vial.

The single highest-value change most people can make is buying a cheap logging thermometer, because it converts an assumption about their storage into a record.

shareimprove this answerflag
SC
answered · acceptedstopper_core50k13823 Jan 2026
7Thank you — the worked example is what makes this usable. – Dr_Sara_Kuusela 4 months ago
6Related: the same reasoning applies to the counter-ion question. – Dr_Yusuf_Adeyemi 3 months ago
add a comment
Sponsored

Sigma-Aldrich - Certified Reference Materials

Analytical standards and reagents with traceable certificates. Every quantitative result you read inherits the accuracy of the standard behind it.

Shop standards
17

Mechanically, freeze-thaw damage happens at the moving ice front, not at the storage temperature. Once the sample is frozen solid and cold, very little is happening. The damage is done during freezing and thawing, which is why the number of cycles matters and the duration of the hold mostly does not.

Freeze-concentration is the mechanism people miss. As ice forms, everything that is not water is excluded into a shrinking unfrozen fraction, so the local concentration of peptide, buffer salts and preservative rises sharply. If the buffer components crystallise at different rates, local pH can shift by more than a unit. That is why a phosphate-buffered solution can behave badly on freezing while an unbuffered one is fine.

A domestic freezer holds roughly minus eighteen degrees and cycles by several degrees on its defrost schedule, which for a lyophilised solid is entirely adequate and for a frozen solution means repeated partial melting at the surface. If you are going to freeze a solution, an unopened chest freezer is materially better than the compartment in the top of a fridge.

The practical rule is that time and temperature multiply, so shorten whichever one you control.

shareimprove this answerflag
EV
answeredesther_vandeVelde49k3830 Apr 2026
7

On the detail: the lyophilised solid is far more robust than anything anyone says about it, and the solution is far less robust. Most of the confusion in this area comes from advice about one being applied to the other.

The 28-day figure for a reconstituted preserved vial is microbiological, not chemical. Chemically, a well-behaved peptide at 5 mg/mL at 4 °C will typically lose well under a per cent of content per month. The reason to respect the date is bioburden, and bioburden is a function of how many times you have opened it, not of the calendar.

Aggregation is the failure mode that reverse-phase HPLC is worst at detecting, because a large soluble aggregate may not elute at all and an insoluble one is filtered out during sample preparation. If your purity result comes back normal but the vial looks hazy, believe the vial. Size-exclusion chromatography is the method that sees this.

One qualification: none of this addresses sterility. A vial can be chemically pristine and microbiologically compromised, and a chromatogram will not tell you which.

Minimise transitions rather than minimising temperature. One freeze and one thaw is fine; five is a different question.

shareimprove this answerflag
JF
answeredjuliette_farnese12k283 Feb 2026
5Worth flagging that this changed in 2025, so older answers on the site are out of date. – juliette_farnese 4 months ago
add a comment
4

Degradation is not one process, and which one dominates depends on the condition you are asking about. In solution at refrigerated temperature the rate-limiting pathway is usually deamidation and hydrolysis; at room temperature aggregation overtakes them; frozen, the damage happens during the transitions rather than during the hold.

Light matters for specific residues rather than in general. Tryptophan and to a lesser extent tyrosine and methionine are photo-labile; a sequence without them is largely indifferent to ambient light over the timescales in question. Amber glass is cheap insurance rather than a requirement.

Store solid, store cold, store dry, and reconstitute what you will use rather than what fits in the vial.

shareimprove this answerflag
DA
answeredDr_Yusuf_Adeyemi95k24814 Feb 2026
3Does this hold at lower concentrations, or does adsorption dominate? – marta_okonkwo 8 months ago
4Worth flagging that this changed in 2025, so older answers on the site are out of date. – v_ramaswamy 10 months ago
add a comment
-3

The honest answer is that published stability data for these specific molecules in a research-grade presentation essentially does not exist, so what you get is extrapolation from the licensed formulations and from general peptide chemistry. That extrapolation is reasonable. It is still extrapolation.

Adsorption to the container is a real loss at low concentration. For a peptide at 0.1 mg/mL in an untreated glass vial, single-digit percentage losses to the wall are plausible; at 5 mg/mL it is negligible. This is one of several reasons not to reconstitute to a very dilute working solution and store it.

If the material arrived warm and it was lyophilised, test it and proceed on the result. If it arrived warm and it was in solution, the result is more likely to be interesting than reassuring.

edited 17 May 2026 by ines_brandt — tightened the wording; no substantive change

shareimprove this answerflag
IB
answeredines_brandt93k24812 May 2026

Your answer

Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.

Not medical advice. Research-use-only compounds are not approved for human use.